KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Incyte (INCY) Change in Accured Expenses: 2010-2025

Historic Change in Accured Expenses for Incyte (INCY) over the last 16 years, with Sep 2025 value amounting to $115.1 million.

  • Incyte's Change in Accured Expenses fell 5.43% to $115.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.0 million, marking a year-over-year decrease of 159.15%. This contributed to the annual value of $278.9 million for FY2024, which is 20.95% up from last year.
  • Latest data reveals that Incyte reported Change in Accured Expenses of $115.1 million as of Q3 2025, which was up 124.15% from -$476.7 million recorded in Q2 2025.
  • Incyte's 5-year Change in Accured Expenses high stood at $129.8 million for Q4 2024, and its period low was -$476.7 million during Q2 2025.
  • Its 3-year average for Change in Accured Expenses is $20.3 million, with a median of $74.8 million in 2025.
  • In the last 5 years, Incyte's Change in Accured Expenses skyrocketed by 2,430.46% in 2022 and then plummeted by 510.90% in 2025.
  • Quarterly analysis of 5 years shows Incyte's Change in Accured Expenses stood at $46.4 million in 2021, then climbed by 3.04% to $47.8 million in 2022, then surged by 143.08% to $116.2 million in 2023, then climbed by 11.66% to $129.8 million in 2024, then fell by 5.43% to $115.1 million in 2025.
  • Its Change in Accured Expenses was $115.1 million in Q3 2025, compared to -$476.7 million in Q2 2025 and $74.8 million in Q1 2025.